Published online 4 May 2005
Article |
Inhibition of double-strand break non-homologous end-joining by cisplatin adducts in human cell extracts
Cancer Research UK Clinical Centre, St James's University Hospital Leeds LS9 7TF, UK
*To whom correspondence should be addressed. Tel: +44 113 206 4908; Fax: +44 113 242 9886; Email: anne.kiltie{at}cancer.org.uk
Received December 2, 2004. Revised February 25, 2005. Accepted April 4, 2005.
The effect of cis-diaminedichloroplatinum(II) (cisplatin) DNA damage on the repair of double-strand breaks by non-homologous end-joining (NHEJ) was determined using cell-free extracts. NHEJ was dramatically decreased when plasmid DNA was damaged to contain multiple types of DNA adducts, along the molecule and at the termini, by incubation of DNA with cisplatin; this was a cisplatin concentration-dependent effect. We investigated the effect a single GTG cisplatination site starting 10 bp from the DNA termini would have when surrounded by the regions of AT-rich DNA which were devoid of the major adduct target sequences. Cisplatination of a substrate containing short terminal 13–15 bp AT-rich sequences reduced NHEJ to a greater extent than that of a substrate with longer (31–33 bp) AT-rich sequences. However, cisplatination at the single GTG site within the AT sequence had no significant effect on NHEJ, owing to the influence of additional minor monoadduct and dinucleotide adduct sites within the AT-rich region and owing to the influence of cisplatination at sites upstream of the AT-rich regions. We then studied the effect on NHEJ of one cis-[Pt(NH3)2{d(GpTpG)-N7(1),-N7(3)} [abbreviated as 1,3-d(GpTpG)] cisplatin adduct in the entire DNA molecule, which is more reflective of the situation in vivo during concurrent chemoradiation. The presence of a single 1,3-d(GpTpG) cisplatin adduct 10 bases from each of the two DNA ends to be joined resulted in a small (30%) but significant decrease in NHEJ efficiency. This process, which was DNA-dependent protein kinase and Ku dependent, may in part explain the radiosensitizing effect of cisplatin administered during concurrent chemoradiation.
Correspondence may also be addressed to C. P. Diggle. Tel: +44 113 206 5674; Fax: +44 113 244 4475; Email: c.p.diggle{at}leeds.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Sak, S. Grehl, M. Engelhard, A. Wierlemann, H.-P. Kaelberlah, P. Erichsen, C. Pottgen, M. Groneberg, and M. Stuschke Long-Term In vivo Effects of Cisplatin on {gamma}-H2AX Foci Signaling in Peripheral Lymphocytes of Tumor Patients After Irradiation Clin. Cancer Res., April 15, 2009; 15(8): 2927 - 2934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Smeaton, P. S. Miller, G. Ketner, and L. A. Hanakahi Small-scale extracts for the study of nucleotide excision repair and non-homologous end joining Nucleic Acids Res., December 10, 2007; (2007) gkm974v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yonetani, H. Hochegger, E. Sonoda, S. Shinya, H. Yoshikawa, S. Takeda, and M. Yamazoe Differential and collaborative actions of Rad51 paralog proteins in cellular response to DNA damage Nucleic Acids Res., August 10, 2005; 33(14): 4544 - 4552. [Abstract] [Full Text] [PDF]
|
|